Which quadruple therapy should be prescribed as first-line treatment for Helicobacter pylori infection? Results of a prospective study comparing concomitant and bismuth therapy - PubMed
4 hours ago
- #antibiotic resistance
- #quadruple therapy
- #Helicobacter pylori
- Study compares two quadruple therapies for H. pylori infection: concomitant (QC-14) and bismuth-based (QB-10).
- Both therapies showed similar eradication rates: 79.5% for QB-10 and 76.1% for QC-14.
- Adverse events were comparable, with diarrhea more frequent in QC-14 and discolored stools only in QB-10.
- Adherence rates were high (>93%) in both groups.
- The study suggests that either therapy is effective, with choice depending on local resistance, cost, and patient factors.